Loading
A phase 1/2 trial of Pembrolizumab in metastatic cancer and ovarian cancer, run by PMV Pharmaceuticals, Inc, now recruiting.
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is a phase 1/2 interventional study registered as NCT04585750 by PMV Pharmaceuticals, Inc, with 300 participants planned, started 2020-10-29 and due to reach its primary completion in 2026-12-15. Interventions recorded: rezatapopt, pembrolizumab. Conditions listed: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor. No results are recorded here; the registry entry is the source.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer, Pembrolizumab.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer, Immune checkpoint inhibitors.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer, Ovarian cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer, Ovarian cancer.